Whitney Ijem
Stock Analyst at Canaccord Genuity
(4.50)
# 283
Out of 5,044 analysts
108
Total ratings
52.69%
Success rate
24.39%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Whitney Ijem
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PVLA Palvella Therapeutics | Maintains: Buy | $66 → $90 | $73.50 | +22.45% | 6 | Oct 9, 2025 | |
| GBIO Generation Bio Co. | Maintains: Buy | $9 → $10 | $5.80 | +72.56% | 3 | Aug 18, 2025 | |
| PASG Passage Bio | Maintains: Buy | $260 → $67 | $7.66 | +774.67% | 7 | Aug 14, 2025 | |
| GUTS Fractyl Health | Maintains: Buy | $12 → $6 | $1.28 | +368.75% | 1 | Aug 14, 2025 | |
| TSHA Taysha Gene Therapies | Maintains: Buy | $11 → $14 | $4.99 | +180.56% | 11 | Aug 13, 2025 | |
| RARE Ultragenyx Pharmaceutical | Maintains: Buy | $136 → $128 | $34.77 | +268.13% | 9 | Aug 8, 2025 | |
| VRTX Vertex Pharmaceuticals | Maintains: Hold | $424 → $411 | $422.39 | -2.70% | 9 | Aug 6, 2025 | |
| WVE Wave Life Sciences | Initiates: Buy | $19 | $7.59 | +150.33% | 1 | Aug 4, 2025 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Buy | $390 → $415 | $475.91 | -12.80% | 9 | Aug 1, 2025 | |
| RCKT Rocket Pharmaceuticals | Maintains: Buy | $11 → $10 | $3.97 | +151.89% | 9 | Jul 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $92 → $105 | $113.46 | -7.46% | 8 | Jul 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $74 → $54 | $13.96 | +286.82% | 6 | Jun 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $68 → $66 | $9.88 | +568.02% | 6 | May 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $18 → $6 | $1.56 | +284.62% | 6 | Mar 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $148 → $150 | $24.22 | +519.32% | 3 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $93 → $84 | $53.49 | +57.04% | 8 | Oct 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $117.88 | - | 2 | Jan 21, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $120 → $240 | $6.33 | +3,691.47% | 4 | Jul 23, 2019 |
Palvella Therapeutics
Oct 9, 2025
Maintains: Buy
Price Target: $66 → $90
Current: $73.50
Upside: +22.45%
Generation Bio Co.
Aug 18, 2025
Maintains: Buy
Price Target: $9 → $10
Current: $5.80
Upside: +72.56%
Passage Bio
Aug 14, 2025
Maintains: Buy
Price Target: $260 → $67
Current: $7.66
Upside: +774.67%
Fractyl Health
Aug 14, 2025
Maintains: Buy
Price Target: $12 → $6
Current: $1.28
Upside: +368.75%
Taysha Gene Therapies
Aug 13, 2025
Maintains: Buy
Price Target: $11 → $14
Current: $4.99
Upside: +180.56%
Ultragenyx Pharmaceutical
Aug 8, 2025
Maintains: Buy
Price Target: $136 → $128
Current: $34.77
Upside: +268.13%
Vertex Pharmaceuticals
Aug 6, 2025
Maintains: Hold
Price Target: $424 → $411
Current: $422.39
Upside: -2.70%
Wave Life Sciences
Aug 4, 2025
Initiates: Buy
Price Target: $19
Current: $7.59
Upside: +150.33%
Alnylam Pharmaceuticals
Aug 1, 2025
Maintains: Buy
Price Target: $390 → $415
Current: $475.91
Upside: -12.80%
Rocket Pharmaceuticals
Jul 25, 2025
Maintains: Buy
Price Target: $11 → $10
Current: $3.97
Upside: +151.89%
Jul 18, 2025
Maintains: Buy
Price Target: $92 → $105
Current: $113.46
Upside: -7.46%
Jun 3, 2025
Maintains: Buy
Price Target: $74 → $54
Current: $13.96
Upside: +286.82%
May 13, 2025
Maintains: Buy
Price Target: $68 → $66
Current: $9.88
Upside: +568.02%
Mar 13, 2025
Maintains: Buy
Price Target: $18 → $6
Current: $1.56
Upside: +284.62%
Nov 7, 2024
Maintains: Buy
Price Target: $148 → $150
Current: $24.22
Upside: +519.32%
Oct 30, 2024
Maintains: Hold
Price Target: $93 → $84
Current: $53.49
Upside: +57.04%
Jan 21, 2020
Downgrades: Neutral
Price Target: n/a
Current: $117.88
Upside: -
Jul 23, 2019
Upgrades: Overweight
Price Target: $120 → $240
Current: $6.33
Upside: +3,691.47%